Author:
Luvira Viravarn,Watthanakulpanich Dorn
Reference8 articles.
1. Optimizing moxidectin dosing for Strongyloides stercoralis infections: insights from pharmacometric modeling;Hofmann;Clin Transl Sci,2022
2. Efficacy of moxidectin versus ivermectin against Strongyloides stercoralis infections: a randomized, controlled noninferiority trial;Barda;Clin Infect Dis,2017
3. Efficacy and safety of ascending doses of moxidectin against Strongyloides stercoralis infections in adults: a randomised, parallel-group, single-blinded, placebo-controlled, dose-ranging, phase 2a trial;Hofmann;Lancet Infect Dis,2021
4. Efficacy and safety of moxidectin compared with ivermectin against Strongyloides stercoralis infection in adults in Laos and Cambodia: a randomised, double-blind, non-inferiority, phase 2b/3 trial;Sprecher;Lancet Infect Dis,2023
5. Repeated ivermectin treatment induces ivermectin resistance in Strongyloides ratti by upregulating the expression of ATP-binding cassette transporter genes;Sengthong;Am J Trop Med Hyg,2021